Financhill
Sell
41

BMY Quote, Financials, Valuation and Earnings

Last price:
$54.91
Seasonality move :
1.39%
Day range:
$54.12 - $54.98
52-week range:
$39.35 - $61.10
Dividend yield:
4.4%
P/E ratio:
--
P/S ratio:
2.31x
P/B ratio:
6.83x
Volume:
10.6M
Avg. volume:
11M
1-year change:
10.27%
Market cap:
$111.6B
Revenue:
$48.3B
EPS (TTM):
-$4.42

Analysts' Opinion

  • Consensus Rating
    Bristol-Myers Squibb has received a consensus rating of Hold. The company's average rating is a Hold based on 3 Buy ratings, 17 Hold ratings, and 1 Sell rating.
  • Price Target Upside
    According to analysts' consensus price target of $61.34, Bristol-Myers Squibb has an estimated upside of 11.57% from its current price of $54.98.
  • Price Target Downside
    According to analysts, the lowest downside price target is $37.00 representing 32.7% downside risk from its current price of $54.98.

Fair Value

  • According to the consensus of 21 analysts, Bristol-Myers Squibb has 11.57% upside to fair value with a price target of $61.34 per share.

BMY vs. S&P 500

  • Over the past 5 trading days, Bristol-Myers Squibb has underperformed the S&P 500 by -2.19% suggesting its relative strength compared to the major market average is weak at this time.

Share Buyback

  • Bristol-Myers Squibb does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • Bristol-Myers Squibb has grown year-over-year revenues for 5 quarters straight. In the most recent quarter Bristol-Myers Squibb reported revenues of $12.3B.

Earnings Growth

  • Bristol-Myers Squibb earnings have been falling on a year-over-year basis for 3 quarters in a row. In the most recent quarter Bristol-Myers Squibb reported earnings per share of $0.04.
Enterprise value:
150.4B
EV / Invested capital:
2.28x
Price / LTM sales:
2.31x
EV / EBIT:
--
EV / Revenue:
3.11x
PEG ratio (5yr expected):
--
EV / Free cash flow:
10.79x
Price / Operating cash flow:
8.00x
Enterprise value / EBITDA:
47.48x
Gross Profit (TTM):
$34.3B
Return On Assets:
-9.42%
Net Income Margin (TTM):
-18.53%
Return On Equity:
-46.27%
Return On Invested Capital:
-13.01%
Operating Margin:
4.13%
Trailing 12 Months Fiscal Quarters
Period Ending 2022-12-31 2023-12-31 2024-12-31 2023-12-31 2024-12-31
Income Statement
Revenue $46.2B $45B $48.3B $11.5B $12.3B
Gross Profit $36B $34.3B $34.3B $8.7B $7.5B
Operating Income $9.1B $8.2B $5.9B $1.9B $510M
EBITDA $19.2B $19.4B $3.2B $4.5B $2.6B
Diluted EPS $2.95 $3.86 -$4.42 $0.87 $0.04
Period Ending 2020-12-31 2021-12-31 2022-12-31 2023-12-31 2024-12-31
Balance Sheet
Current Assets $30.2B $33.3B $27.3B $31.8B $29.8B
Total Assets $118.5B $109.3B $96.8B $95.2B $92.6B
Current Liabilities $19.1B $21.9B $21.9B $22.3B $23.8B
Total Liabilities $80.6B $73.3B $65.7B $65.7B $76.2B
Total Equity $37.9B $36B $31.1B $29.5B $16.4B
Total Debt $50.7B $44.6B $39.3B $39.8B $49.6B
Trailing 12 Months Fiscal Quarters
Period Ending 2022-12-31 2023-12-31 2024-12-31 2023-12-31 2024-12-31
Cash Flow Statement
Cash Flow Operations $13.1B $13.9B $15.2B $4.3B $4.4B
Cash From Investing -$1.1B -$2.3B -$21.4B -$1.3B -$196M
Cash From Financing -$17B -$9.4B $5.1B $967M -$1.6B
Free Cash Flow $11.9B $12.7B $13.9B $3.9B $4.1B
BMY
Sector
Market Cap
$111.6B
$44.2M
Price % of 52-Week High
89.98%
48.19%
Dividend Yield
4.4%
0%
Shareholder Yield
2.14%
-0.68%
1-Year Price Total Return
10.27%
-35.43%
Beta (5-Year)
0.452
0.747
Dividend yield:
4.4%
Annualized payout:
$2.40
Payout ratio:
-54.35%
Growth streak:
3 years

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Technicals

8-day SMA
Sell
Level $55.47
200-day SMA
Buy
Level $50.47
Bollinger Bands (100)
Sell
Level 53.46 - 58.64
Chaikin Money Flow
Buy
Level 695M
20-day SMA
Sell
Level $57.62
Relative Strength Index (RSI14)
Sell
Level 40.33
ADX Line
Sell
Level 23.55
Williams %R
Neutral
Level -78.8856
50-day SMA
Sell
Level $57.21
MACD (12, 26)
Sell
Level -0.71
25-day Aroon Oscillator
Sell
Level -60
On Balance Volume
Neutral
Level 470M

Financial Scores

Sell
Altman Z-Score (Annual)
Level (1.4991)
Sell
CA Score (Annual)
Level (-1.7489)
Buy
Beneish M-Score (Annual)
Level (-3.72)
Buy
Momentum Score
Level (8)
Buy
Ohlson Score
Level (-0.0536)
Buy
Piotroski F Score (Annual)
Level (4)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (7)

Revenue Forecast

Earnings per Share Forecast

Company Profile

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.

Stock Forecast FAQ

In the current month, BMY has received 3 Buy ratings 17 Hold ratings, and 1 Sell ratings. The BMY average analyst price target in the past 3 months is $61.34.

  • Where Will Bristol-Myers Squibb Stock Be In 1 Year?

    According to analysts, the consensus estimate is that Bristol-Myers Squibb share price will rise to $61.34 per share over the next 12 months.

  • What Do Analysts Say About Bristol-Myers Squibb?

    Analysts are divided on their view about Bristol-Myers Squibb share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Bristol-Myers Squibb is a Sell and believe this share price will drop from its current level to $37.00.

  • What Is Bristol-Myers Squibb's Price Target?

    The price target for Bristol-Myers Squibb over the next 1-year time period is forecast to be $61.34 according to 21 Wall Street analysts, 3 of them rate the stock a Buy, 1 rates the stock a Sell, and 17 analysts rate the stock a Hold.

  • Is BMY A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for Bristol-Myers Squibb is a Hold. 17 of 21 analysts rate the stock a Hold at this time.

  • How Can I Buy Shares Of BMY?

    You can purchase shares of Bristol-Myers Squibb via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Bristol-Myers Squibb shares.

  • What Is The Bristol-Myers Squibb Share Price Today?

    Bristol-Myers Squibb was last trading at $54.91 per share. This represents the most recent stock quote for Bristol-Myers Squibb. Yesterday, Bristol-Myers Squibb closed at $54.98 per share.

  • How To Buy Bristol-Myers Squibb Stock Online?

    In order to purchase Bristol-Myers Squibb stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is CVX a Buy, Sell or Hold?
Is CVX a Buy, Sell or Hold?

Energy giant Chevron Corporation (NYSE:CVX) has long been a pure-play…

What Will NVIDIA Stock Be Worth in 2030?
What Will NVIDIA Stock Be Worth in 2030?

NVIDIA (NASDAQ:NVDA) has been by far one of the best…

How Low Could Tesla Go?
How Low Could Tesla Go?

Shares of EV major Tesla (NASDAQ:TSLA) have been defying gravity…

Stock Ideas

Buy
64
Is AAPL Stock a Buy?

Market Cap: $3.7T
P/E Ratio: 40x

Buy
60
Is NVDA Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 117x

Buy
51
Is MSFT Stock a Buy?

Market Cap: $3.1T
P/E Ratio: 35x

Alerts

Sell
8
PRG alert for Feb 20

PROG Holdings [PRG] is down 0.75% over the past day.

Sell
21
CE alert for Feb 20

Celanese [CE] is down 4.79% over the past day.

Sell
22
GLBE alert for Feb 20

Global E Online [GLBE] is down 6.37% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock